STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG) today announces that Management will participate in the upcoming investor events set out below.
Transgene will meet institutional investors from January 7 to 11, 2018, in San Francisco, USA, concurrent with the J.P. Morgan Healthcare conference.
The Company will also attend:
- Oddo Forum: January 11 & 12, 2018 – Lyon, France
- Portzamparc MidCap Conference: April 4, 2018 – Paris, France
- Small Cap Event: April 16 & 17, 2018 – Paris, France
- Kempen Life Sciences Conference: April 18 & 19, 2018 – Amsterdam, Netherlands
About Transgene
Transgene (Euronext Paris: TNG), part
of Institut Mérieux, is a publicly traded French biotechnology company
focused on designing and developing targeted immunotherapies for the
treatment of cancer and infectious diseases. Transgene’s programs
utilize viral vector technology with the goal of indirectly or directly
killing infected or cancerous cells. The Company’s lead clinical-stage
programs are: TG4010, a therapeutic vaccine against non-small cell lung
cancer, Pexa-Vec, an oncolytic virus against liver cancer, and TG4001, a
therapeutic vaccine against HPV-positive head and neck cancers. The
Company has several other programs in clinical and preclinical
development, including TG1050 (chronic hepatitis B) and TG6002 (solid
tumors). Transgene is based in Strasbourg, France, and has additional
operations in Lyon, as well as a joint venture in China.
Additional
information about Transgene is available at www.transgene.fr.
Follow
us on Twitter: @TransgeneSA
